Search Results - "Ginzler, E."

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE by Dooley, MA, Houssiau, F, Aranow, C, D’Cruz, DP, Askanase, A, Roth, DA, Zhong, ZJ, Cooper, S, Freimuth, WW, Ginzler, EM

“…A pooled post-hoc analysis of the phase 3, randomized, placebo-controlled BLISS trials (1684 patients with active systemic lupus erythematosus (SLE)) was…”
Get full text

Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis by Ginzler, Ellen M, Dooley, Mary Anne, Aranow, Cynthia, Kim, Mimi Y, Buyon, Jill, Merrill, Joan T, Petri, Michelle, Gilkeson, Gary S, Wallace, Daniel J, Weisman, Michael H, Appel, Gerald B

“…This 24-week randomized, open-label, noninferiority trial compared oral mycophenolate mofetil with monthly intravenous cyclophosphamide as induction therapy…”
Get full text

The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials by Rovin, B H, Dooley, M A, Radhakrishnan, J, Ginzler, E M, Forrester, T D, Anderson, P W

“…Introduction Tabalumab is a monoclonal antibody that neutralizes membrane and soluble B-cell activating factor. Two 52-week, randomized, double-blind, placebo…”
Get full text

Current treatment of lupus nephritis by Houssiau, FA, Ginzler, EM

“…This review on the management of lupus nephritis is based on the results of randomized clinical trials, and discusses the principles of treatment and the…”
Get full text

An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA by Isenberg, D A, Allen, E, Farewell, V, D'Cruz, D, Alarcón, G S, Aranow, C, Bruce, I N, Dooley, M A, Fortin, P R, Ginzler, E M, Gladman, D D, Hanly, J G, Inanc, M, Kalunian, K, Khamashta, M, Merrill, J T, Nived, O, Petri, M, Ramsey-Goldman, R, Sturfelt, G, Urowitz, M, Wallace, D J, Gordon, C, Rahman, A

“…To compare the British Isles Lupus Assessment Group (BILAG) 2004, the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) flare index (SFI)…”
Get more information

Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus by Hanly, J G, Urowitz, M B, Su, L, Bae, S C, Gordon, C, Wallace, D J, Clarke, A, Bernatsky, S, Isenberg, D, Rahman, A, Alarcón, G S, Gladman, D D, Fortin, P R, Sanchez-Guerrero, J, Romero-Diaz, J, Merrill, J T, Ginzler, E, Bruce, I N, Steinsson, K, Khamashta, M, Petri, M, Manzi, S, Dooley, M A, Ramsey-Goldman, R, Van Vollenhoven, R, Nived, O, Sturfelt, G, Aranow, C, Kalunian, K, Ramos-Casals, M, Zoma, A, Douglas, J, Thompson, K, Farewell, V

“…To determine the frequency, accrual, attribution and outcome of neuropsychiatric (NP) events and impact on quality of life over 3 years in a large inception…”
Get more information

Anti-C1q antibodies in systemic lupus erythematosus by Orbai, A-M, Truedsson, L, Sturfelt, G, Nived, O, Fang, H, Alarcón, G S, Gordon, C, Merrill, JT, Fortin, P R, Bruce, I N, Isenberg, D A, Wallace, D J, Ramsey-Goldman, R, Bae, S-C, Hanly, J G, Sanchez-Guerrero, J, Clarke, A E, Aranow, C B, Manzi, S, Urowitz, M B, Gladman, D D, Kalunian, K C, Costner, M I, Werth, V P, Zoma, A, Bernatsky, S, Ruiz-Irastorza, G, Khamashta, M A, Jacobsen, S, Buyon, J P, Maddison, P, Dooley, M A, Van Vollenhoven, R F, Ginzler, E, Stoll, T, Peschken, C, Jorizzo, J L, Callen, J P, Lim, S S, Fessler, B J, Inanc, M, Kamen, D L, Rahman, A, Steinsson, K, Franks, A G, Sigler, L, Hameed, S, Pham, N, Brey, R, Weisman, M H, McGwin, G, Magder, L S, Petri, M

“…Objective Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE…”
Get full text

Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study by Hanly, John G, Urowitz, Murray B, Su, Li, Gordon, Caroline, Bae, Sang-Cheol, Sanchez-Guerrero, Jorge, Romero-Diaz, Juanita, Wallace, Daniel J, Clarke, Ann E, Ginzler, Em, Merrill, Joan T, Isenberg, David A, Rahman, Anisur, Petri, M, Fortin, Paul R, Gladman, Dd, Bruce, Ian N, Steinsson, Kristjan, Dooley, Ma, Khamashta, Munther A, Alarcón, Graciela S, Fessler, Barri J, Ramsey-Goldman, Rosalind, Manzi, Susan, Zoma, Asad A, Sturfelt, Gunnar K, Nived, Ola, Aranow, Cynthia, Mackay, Meggan, Ramos-Casals, Manuel, van Vollenhoven, Rf, Kalunian, Kenneth C, Ruiz-Irastorza, Guillermo, Lim, Sam, Kamen, Diane L, Peschken, Christine A, Inanc, Murat, Theriault, Chris, Thompson, Kara, Farewell, Vernon

“…The aim of this study was to describe the frequency, attribution, outcome and predictors of seizures in systemic lupus erythematosus (SLE). The Systemic Lupus…”
Get more information

The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study by Bernatsky, S, Joseph, L, Boivin, J-F, Gordon, C, Urowitz, M, Gladman, D, Fortin, P R, Ginzler, E, Bae, S-C, Barr, S, Edworthy, S, Isenberg, D, Rahman, A, Petri, M, Alarcón, G S, Aranow, C, Dooley, M-A, Rajan, R, Sénécal, J-L, Zummer, M, Manzi, S, Ramsey-Goldman, R, Clarke, A E

“…To examine if, in systemic lupus erythaematosus (SLE), exposure to immunosuppressive therapy (cyclophosphamide, azathioprine, methotrexate) increases cancer…”
Get more information

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort by Urowitz, M. B., Gladman, D. D., Ibañez, D., Fortin, P. R., Bae, S. C., Gordon, C., Clarke, A., Bernatsky, S., Hanly, J. G., Isenberg, D., Rahman, A., Sanchez‐Guerrero, J., Wallace, D. J., Ginzler, E., Alarcón, G. S., Merrill, J. T., Bruce, I. N., Sturfelt, G., Nived, O., Steinsson, K., Khamashta, M., Petri, M., Manzi, S., Ramsey‐Goldman, R., Dooley, M. A., van Vollenhoven, R. F., Ramos, M., Stoll, T., Zoma, A., Kalunian, K., Aranow, C.

“…Objective We describe disease activity, damage, and the accrual of key autoantibodies in an inception systemic lupus erythematosus (SLE) cohort. Methods The…”
Get full text

Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus by Urowitz, M. B., Gladman, D., Ibañez, D., Bae, S. C., Sanchez‐Guerrero, J., Gordon, C., Clarke, A., Bernatsky, S., Fortin, P. R., Hanly, J. G., Wallace, D. J., Isenberg, D., Rahman, A., Alarcón, G. S., Merrill, J. T., Ginzler, E., Khamashta, M., Nived, O., Sturfelt, G., Bruce, I. N., Steinsson, K., Manzi, S., Ramsey‐Goldman, R., Dooley, M. A., Zoma, A., Kalunian, K., Ramos, M., Van Vollenhoven, R. F., Aranow, C., Stoll, T., Petri, M., Maddison, P.

“…Objective To describe vascular events during an 8‐year followup in a multicenter systemic lupus erythematosus (SLE) inception cohort and their attribution to…”
Get full text

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis by Dooley, Mary Anne, Jayne, David, Ginzler, Ellen M, Isenberg, David, Olsen, Nancy J, Wofsy, David, Eitner, Frank, Appel, Gerald B, Contreras, Gabriel, Lisk, Laura, Solomons, Neil

“…In this double-blind, randomized trial, mycophenolate mofetil was superior to azathioprine for maintaining a renal response and preventing relapse in patients…”
Get full text

International consensus for a definition of disease flare in lupus by Ruperto, N, Hanrahan, LM, Alarcón, GS, Belmont, HM, Brey, RL, Brunetta, P, Buyon, JP, Costner, MI, Cronin, ME, Dooley, MA, Filocamo, G, Fiorentino, D, Fortin, PR, Franks, AG, Gilkeson, G, Ginzler, E, Gordon, C, Grossman, J, Hahn, B, Isenberg, DA, Kalunian, KC, Petri, M, Sammaritano, L, Sánchez-Guerrero, J, Sontheimer, RD, Strand, V, Urowitz, M, von Feldt, JM, Werth, VP, Merrill, JT

“…The Lupus Foundation of America (LFA) convened an international working group to obtain a consensus definition of disease flare in lupus. With help from the…”
Get full text

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients by Isenberg, D., Sturgess, J., Allen, E., Aranow, C., Askanase, A., Sang‐Cheol, B., Bernatsky, S., Bruce, I., Buyon, J., Cervera, R., Clarke, A., Dooley, Mary Anne, Fortin, P., Ginzler, E., Gladman, D., Hanly, J., Inanc, M., Jacobsen, S., Kamen, D., Khamashta, M., Lim, S., Manzi, S., Nived, O., Peschken, C., Petri, M., Kalunian, K., Rahman, A., Ramsey‐Goldman, R., Romero‐Diaz, J., Ruiz‐Irastorza, G., Sanchez‐Guerrero, J., Steinsson, K., Sturfelt, G., Urowitz, M., Vollenhoven, R., Wallace, D. J., Zoma, A., Merrill, J., Gordon, C.

“…Objective To determine the level of agreement of disease flare severity (distinguishing severe, moderate, and mild flare and persistent disease activity) in a…”
Get full text

Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment by Chan, K, Clarke, A E, Ramsey-Goldman, R, Foulkes, W, Tessier Cloutier, B, Urowitz, M B, Gladman, D, Nived, O, Romero-Diaz, J, Petri, M, Ginzler, E, Fortin, P R, Bae, S C, Wallace, D J, Yelin, E H, Bernatsky, S

“…Objective There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the…”
Get full text

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) by Sinclair, A., Appel, G., Dooley, M.A., Ginzler, E., Isenberg, D., Jayne, D., Wofsy, D., Solomons, N.

“…The Phase III Aspreva Lupus Management Study (ALMS) will investigate mycophenolate mofetil (MMF) therapy for lupus nephritis (LN). Eligibility criteria…”
Get full text

Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus by Urowitz, M., Gladman, D. D., Ibañez, D., Sanchez‐Guerrero, J., Bae, S. C., Gordon, C., Fortin, P. R., Clarke, A., Bernatsky, S., Hanly, J. G., Wallace, D. J., Isenberg, D., Rahman, A., Merrill, J., Ginzler, E., Alarcón, G. S., Fessler, B., Khamashta, M., Steinsson, K., Petri, M., Dooley, M., Bruce, I. N., Manzi, S., Sturfelt, G., Nived, O., Ramsey‐Goldman, R., Zoma, A., Maddison, P., Kalunian, K., Vollenhoven, R., Aranow, C., Romero Diaz, J., Stoll, T.

“…Objective The Medical Outcomes Study Short Form 36 (SF‐36) is recommended to assess quality of life (QOL) in systemic lupus erythematosus (SLE). The aim of the…”
Get full text

Genetic imprinting of autoantibody repertoires in systemic lupus erythematosus patients by Silverman, G.J, Srikrishnan, R, Germar, K, Goodyear, C.S, Andrews, K.A, Ginzler, E.M, Tsao, B.P

“…Systemic lupus erythematosus (SLE) is an autoimmune disease distinguished by great heterogeneity in clinical manifestations and autoantibody expression. While…”
Get full text

Breast cancer in systemic lupus by Bernatsky, S, Ramsey-Goldman, R, Petri, M, Urowitz, M B, Gladman, D D, Fortin, P F, Ginzler, E, Romero-Diaz, J, Peschken, C, Jacobsen, S, Hanly, J G, Gordon, C, Nived, O, Yelin, E H, Isenberg, D, Rahman, A, Bae, S-C, Joseph, L, Witte, T, Ruiz-Irastorza, G, Aranow, C, Kamen, D, Sturfeldt, G, Foulkes, W D, Hansen, J E, St Pierre, Y, Raymer, P Chrétien, Tessier-Cloutier, B, Clarke, A E

“…Objective There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE…”
Get full text

Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity by Ippolito, A, Wallace, DJ, Gladman, D, Fortin, PR, Urowitz, M, Werth, V, Costner, M, Gordon, C, Alarcón, GS, Ramsey-Goldman, R, Maddison, P, Clarke, A, Bernatsky, S, Manzi, S, Bae, S-C, Merrill, JT, Ginzler, E, Hanly, JG, Nived, O, Sturfelt, G, Sanchez-Guerrero, J, Bruce, I, Aranow, C, Isenberg, D, Zoma, A, Magder, LS, Buyon, J, Kalunian, K, Dooley, MA, Steinsson, K, Vollenhoven, RF van, Stoll, T, Weisman, M, Petri, M

“…Systemic lupus erythematosus (SLE) is characterized by multiple autoantibodies and complement activation. Recent studies have suggested that anti-nuclear…”
Get full text